Skip to main content
TipRanks
Go Ultimate75% OFF

Theriva Biologics (TOVX) Stock Statistics & Valuation Metrics

1,263 Followers

Total Valuation

Theriva Biologics has a market cap or net worth of $6.61M. The enterprise value is $5.28M.

Market Cap
$6.61M
Enterprise Value
$5.28M

Share Statistics

Theriva Biologics has 45,892,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
45,892,670
Owned by Insiders
0.57%
Owned by Institutions
2.80%

Financial Efficiency

Theriva Biologics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -52.10%.

Return on Equity (ROE)
-1.64
Return on Assets (ROA)
-0.66
Return on Invested Capital (ROIC)
-52.10%
Return on Capital Employed (ROCE)
-0.53
Revenue Per Employee
0
Profits Per Employee
-1.58M
Employee Count
16
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Theriva Biologics is -0.58. Theriva Biologics’s PEG ratio is -0.00.

PE Ratio
-0.58
PS Ratio
22.04
PB Ratio
0.62
Price to FCF
-0.61
Price to Operating Cash Flow
-0.61
PEG Ratio
-0.00

Income Statement

In the last 12 months, Theriva Biologics had revenue of 0 and earned -25.25M in profits. Earnings per share was -2.08.

Revenue
0
Gross Profit
-108.00K
Operating Income
-15.02M
Pretax Income
-23.74M
Net Income
-25.25M
EBITDA
-23.63M
Earnings Per Share (EPS)
-2.08

Cash Flow

In the last 12 months, operating cash flow was -10.89M and capital expenditures -11,000, giving a free cash flow of -10.90M billion.

Operating Cash Flow
-10.89M
Free Cash Flow
-10.90M
Free Cash Flow per Share
-0.24

Dividends & Yields

Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-164.90%
Earnings Yield
-131.98%

Stock Price Statistics

Beta
1.36
52-Week Price Change
-47.64%
50-Day Moving Average
0.21
200-Day Moving Average
0.24
Relative Strength Index (RSI)
28.06
Average Volume (3m)
1.88M

Important Dates

Theriva Biologics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 18, 2027
Ex-Dividend Date
―

Financial Position

Theriva Biologics as a current ratio of 1.74, with Debt / Equity ratio of 17.09%

Current Ratio
1.74
Quick Ratio
1.74
Debt to Market Cap
0.89
Net Debt to EBITDA
0.44
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Theriva Biologics has paid 1.51M in taxes.

Income Tax
1.51M
Effective Tax Rate
-0.06

Enterprise Valuation

Theriva Biologics EV to EBITDA ratio is -0.18, with an EV/FCF ratio of -0.14.

EV to Sales
5.22
EV to EBITDA
-0.18
EV to Free Cash Flow
-0.14
EV to Operating Cash Flow
-0.14

Balance Sheet

Theriva Biologics has $8.47M in cash and marketable securities with $3.43M in debt, giving a net cash position of $5.05M billion.

Cash & Marketable Securities
$8.47M
Total Debt
$3.43M
Net Cash
$5.05M
Net Cash Per Share
$0.11
Tangible Book Value Per Share
-$0.18

Margins

Gross margin is -419.67%, with operating margin of -2997.67%, and net profit margin of -2909.33%.

Gross Margin
-419.67%
Operating Margin
-2997.67%
Pretax Margin
-2909.33%
Net Profit Margin
-2909.33%
EBITDA Margin
-2877.00%
EBIT Margin
-2909.33%

Analyst Forecast

The average price target for Theriva Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
95.48%

Scores

Smart Score
―
AI Score
42